{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:32:48Z","timestamp":1786444368673,"version":"build-2736575974"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chiesi Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Mark. Access Health Policy","JMAHP"],"abstract":"<jats:p>Background: Epidermolysis bullosa (EB) is a complex group of rare, inherited skin disorders that blister easily, imposing substantial burden on patients and carers. There is a lack of published evidence in the UK quantifying health-related quality of life in EB patients and carers as utility values suitable for use in Health Technology Assessment (HTA). Methods: A time trade-off (TTO) study was conducted with 120 UK general public members to estimate utility values for EB patient and primary carer vignettes depicting varying EB severity. An exploratory sub-study involving six carer and clinical experts was conducted to estimate utility values of second carers. Results: 115 general public participants were included in the final TTO analysis. Mean utility values declined as disease severity increased, from 0.82 in the least severe state, to 0.54 in the most severe. Carer utilities were higher than the equivalent patient health states, but with a similar pattern of decreasing utility with increasing EB severity, ranging from 0.85 to 0.64. The secondary carer sub-study, in six respondents estimated a second care burden factor relative to the primary carer of 77%. Conclusions: The utilities estimated for both EB patients and their carers have relevance for future economic evaluations and HTA of new EB therapies.<\/jats:p>","DOI":"10.3390\/jmahp14030048","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:11:16Z","timestamp":1786439476000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-Related Quality of Life of Patients with Epidermolysis bullosa and Carers Using a Time Trade-Off Approach in the UK General Population to Elicit Utilities for Health Technology Assessment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0231-4146","authenticated-orcid":false,"given":"Luke","family":"Stainer","sequence":"first","affiliation":[{"name":"Tolley Ltd., Buxton SK17 6EQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2014-3415","authenticated-orcid":false,"given":"George","family":"Morgan","sequence":"additional","affiliation":[{"name":"HCD Economics, The Innovation Centre, Keckwick Ln, Daresbury, Warrington WA4 4FS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Snell","sequence":"additional","affiliation":[{"name":"Tolley Ltd., Buxton SK17 6EQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mather","sequence":"additional","affiliation":[{"name":"DEBRA UK, The Capitol Building, Oldbury, Bracknell RG12 8FZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagair","family":"Hussain","sequence":"additional","affiliation":[{"name":"DEBRA UK, The Capitol Building, Oldbury, Bracknell RG12 8FZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Tolley","sequence":"additional","affiliation":[{"name":"Tolley Ltd., Buxton SK17 6EQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus re-classification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2018.10.017","article-title":"Phenotypic Spectrum of Epidermolysis Bullosa: The Paradigm of Syndromic versus Non-Syndromic Skin Fragility Disorders","volume":"139","author":"Vahidnezhad","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2008.02.004","article-title":"The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB","volume":"58","author":"Fine","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijwd.2014.12.001","article-title":"Prevalence of anemia in patients with epidermolysis bullosa registered in Australia","volume":"1","author":"Hwang","year":"2015","journal-title":"Int. J. Womens Dermatol."},{"key":"ref_6","first-page":"11","article-title":"The epidemiology of epidermolysis bullosa in the UK: Data from the national database","volume":"183","author":"Petrof","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JDN.0b013e31828866fa","article-title":"Recommendations for a Comprehensive Management Plan for the Child Diagnosed With Epidermolysis Bullosa","volume":"5","author":"Badger","year":"2013","journal-title":"J. Dermatol. Nurses Assoc."},{"key":"ref_8","first-page":"185","article-title":"Management of the infant with epidermolysis bullosa","volume":"5","author":"Denyer","year":"2009","journal-title":"Infant"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1750-1172-9-76","article-title":"Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa","volume":"9","author":"Zambruno","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2012.01.016","article-title":"A consensus approach to wound care in epidermolysis bullosa","volume":"67","author":"Pope","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","article-title":"The challenges of living with and managing epidermolysis bullosa: Insights from patients and caregivers","volume":"15","author":"Bruckner","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_13","unstructured":"National Institute for Health and Care Excellence (NICE) (2026, January 25). Birch Bark Extract for Treating Epidermolysis Bullosa. Available online: https:\/\/www.nice.org.uk\/guidance\/hst28."},{"key":"ref_14","unstructured":"Chiesi Limited (2026, January 25). Filsuvez Gel. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/13971\/smpc#gref."},{"key":"ref_15","unstructured":"Scottish Medicines Consortium (SMC) (2026, January 25). Birch Bark Extract (SMC2651). Available online: https:\/\/scottishmedicines.org.uk\/medicines-advice\/birch-bark-extract-filsuvez-uo-pathway-smc2651\/."},{"key":"ref_16","unstructured":"National Institute for Health and Care Excellence (NICE) (2026, January 25). Beremagene Geperpavec for Treating Skin Wounds Associated with Dystrophic Epidermolysis Bullosa [ID3959]. Available online: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10868."},{"key":"ref_17","unstructured":"National Institute for Health and Care Excellence (NICE) (2022). NICE Health Technology Evaluations: The Manual, National Institute for Health and Care Excellence."},{"key":"ref_18","unstructured":"Tolley, K. (2026, January 25). What Are Health Utilities? 2015. Available online: http:\/\/www.medicine.ox.ac.uk\/bandolier\/painres\/download\/whatis\/Health-util.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1477-7525-12-48","article-title":"Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions","volume":"12","author":"Matza","year":"2014","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_20","unstructured":"Rowen, D.W., Wong, A., and R. Wailoo, A. (2020). Measuring and Valuing Health-Related Quality of Life When Sufficient EQ-5D Data Is Not Available, in Report by the Decision Support Unit, The University of Sheffield."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s11136-020-02495-5","article-title":"Quality of life in people with epidermolysis bullosa: A systematic review","volume":"29","author":"Togo","year":"2020","journal-title":"Qual. Life Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/bjd.16350","article-title":"Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB)","volume":"178","author":"Bruckner","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_23","first-page":"352","article-title":"The Estimation of Areas of Burns","volume":"79","author":"Lund","year":"1944","journal-title":"Surg. Gynecol. Obstet."},{"key":"ref_24","unstructured":"Office for National Statistics (2026, January 25). Census, Available online: https:\/\/www.ons.gov.uk\/census."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","article-title":"EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes","volume":"34","author":"Oppe","year":"2016","journal-title":"PharmacoEconomics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jval.2016.10.012","article-title":"Quality Control Process for EQ-5D-5L Valuation Studies","volume":"20","author":"Oppe","year":"2017","journal-title":"Value Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med. Care"},{"key":"ref_28","unstructured":"DEBRA International (2026, January 25). DEBRA\u2014The Butterfly Skin Charity. Available online: https:\/\/www.debra.org.uk\/."},{"key":"ref_29","unstructured":"SurveyMonkey Inc (2026, January 25). SurveyMonkey\u2014Free Online Survey Software. Available online: www.surveymonkey.com."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: Moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"BURQOL-RD Research Network, Angelis, A., Kanavos, P., L\u00f3pez-Bastida, J., Linertov\u00e1, R., Oliva-Moreno, J., Serrano-Aguilar, P., Posada-De-La-Paz, M., Taruscio, D., and Schieppati, A. (2016). Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur. J. Health Econ., 17, 31\u201342.","DOI":"10.1007\/s10198-016-0783-4"},{"key":"ref_32","unstructured":"Janssen, B., and Szende, A. (2026, January 25). Population Norms for the EQ-5D, Self-Reported Population Health: An International Perspective Based on EQ-5D, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500364\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13023-026-04330-5","article-title":"Quality of life reported by individuals with recessive dystrophic epidermolysis bullosa (RDEB): Findings of the Pebles study","volume":"21","author":"Jeffs","year":"2026","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","unstructured":"(2026, January 25). EB Insights Study. Available online: https:\/\/www.debra.org.uk\/pages\/category\/eb-insights-study."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","article-title":"Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: A costing and health-related quality of life study","volume":"17","author":"Angelis","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/j.jval.2022.09.1717","article-title":"Informal carer disutility: How many caregivers are captured in cost-utility analyses of treatments for rare diseases submitted for NICE highly specialised technology appraisals?","volume":"25","author":"Tolley","year":"2022","journal-title":"Value Health"}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:52:53Z","timestamp":1786441973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2001-6689\/14\/3\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jmahp14030048"],"URL":"https:\/\/doi.org\/10.3390\/jmahp14030048","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}